This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ozyar, E. Articles by Genc, M. Search for Related Content PubMed PubMed Citation Articles by Ozyar, E. Articles by Genc, M. Related Articles Related Reply Social Bookmarking                            What's this?

Relapse Pattern of GOG 122 Trial Should Be More Informative

Hacettepe University, Ankara, Turkey

Mine Genc

Selcuk University, Konya, Turkey

To the Editor:

The Gynecologic Oncology Group 122 randomized study compared systemic chemotherapy alone with whole-abdominal irradiation (WAI) in stage III and IV endometrial cancer patients with a maximum of 2 cm of residual disease.¹ This landmark trial showed a significant overall and disease-free survival benefit for patients treated with chemotherapy when compared with WAI. This survival benefit was attributed to significant reduction in distant metastases because the authors concluded that chemotherapy decreased the percentage of initial extra-abdominal failures from 19% to 10%. However, in the analysis of pattern of initial treatment failures, the authors reported that 109 (54%) of 202 patients treated with WAI experienced recurrences of which 27 (13%), 33 (16%), and 45 (22%) were in the pelvis, abdominal, and extra-abdominal regions, respectively. Conversely, 97 (50%) of 194 patients treated with chemotherapy experienced recurrences. The initial site of the recurrence was limited to the pelvis, abdominal, and extra-abdominal regions in 34 (18%), 27 (14%), and 34 (18%) patients, respectively. According to these results, chemotherapy seems to reduce extra-abdominal recurrences only from 22% to 18%. Because the most important conclusion was the reduction of distant metastasis by almost 50% (from 19% to 10%), we believe that this point should be made clear by the authors.

Authors' Disclosures of Potential Conflicts of Interest

The authors indicated no potential conflicts of interest.

REFERENCE

1. Randall ME, Filiaci VL, Muss H, et al: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 24:36-44, 2006[Abstract/Free Full Text]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Reply

• In Reply
  Marcus E. Randall and Virgina L. Filiaci
  JCO 2006 24: 3710 [Full Text]

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ozyar, E. Articles by Genc, M. Search for Related Content PubMed PubMed Citation Articles by Ozyar, E. Articles by Genc, M. Related Articles Related Reply Social Bookmarking                            What's this?